Cannabinoid Acids vs Neutral Forms

Raw cannabis doesn't contain much THC. That's a fact that still surprises people, and honestly it took me longer than I'd like to admit to fully internalise it when I first started mapping the biosynthetic pathway. What the plant actually produces , in abundance , are acidic precursor molecules: THCA, CBDA, CBGA, and a handful of others that don't show up in most everyday conversations about cannabinoids.

The conversion from acid to neutral form is a one-way chemical reaction called decarboxylation. It's well understood, it's simple in principle, and it has significant downstream consequences for how these molecules interact with receptors in the body. Yet it's routinely glossed over. Let's actually look at what's happening.

The biosynthetic starting point: CBGA

CBGA , cannabigerolic acid; sits at the head of the cannabinoid biosynthetic tree. It is the precursor from which most other cannabinoid acids are enzymatically derived. Specific synthase enzymes in the cannabis plant (THCA synthase, CBDA synthase, CBCA synthase) convert CBGA into the major acidic forms. You can think of CBGA as the upstream common currency that the plant spends on making different end products depending on which enzymatic pathways are most active in a given cultivar.

CBG itself, the neutral form, exists in very small quantities in most mature plants, because the plant has already converted most of its CBGA before harvest. Breeders interested in high-CBG material generally harvest earlier to catch the plant before that enzymatic conversion runs to completion.

What decarboxylation actually does

Decarboxylation is the removal of a carboxyl group (-COOH) from the molecule, releasing carbon dioxide in the process. In structural terms, the acidic cannabinoids carry this carboxyl group at the C-2 position of the resorcinyl ring. When that group cleaves off; driven by heat, prolonged light exposure, or simply time, you're left with the neutral (or "active") cannabinoid.

THCA → THC + CO₂. CBDA → CBD + CO₂. The reaction is irreversible under normal conditions.

The temperature dependence here is worth spelling out. THCA begins decarboxylating meaningfully above about 105°C, with near-complete conversion occurring over time at temperatures above 120°C. At ambient temperature and in the dark, the reaction proceeds too, just slowly, over months. This is why old dried cannabis material has generally undergone at least partial decarboxylation even before anyone lights it. It's also why extraction and storage conditions matter to anyone doing analytical chemistry on cannabis samples, because what you're measuring depends on exactly when and how you processed the material.

How the structural difference affects receptor binding

The carboxyl group isn't just a passenger. Its presence on the acidic forms substantially changes the three-dimensional geometry of the molecule and alters its polarity. THCA, for instance, has a binding affinity at the CB1 receptor that is dramatically lower than that of THC. The same pattern holds for CBDA relative to CBD. The neutral forms are considerably more lipophilic, which affects not just receptor binding but bioavailability and distribution across lipid membranes.

This is the core pharmacological reason why raw plant material doesn't produce the same effects as decarboxylated material; the acidic molecules simply don't slot into the classical cannabinoid binding sites in the same way. The endocannabinoid system as we typically describe it, with its CB1 and CB2 receptor architecture, responds to the neutral forms with much greater affinity.

That said, and this is where the picture gets more interesting, acidic cannabinoids aren't inert. They interact with other molecular targets. CBDA, for example, has been investigated for activity at 5-HT₁A serotonin receptors and TRPV1 ion channels, distinct from CBD's profile. THCA has been examined in relation to TRPM8 and PPARγ. Whether these interactions are physiologically significant at concentrations achievable through ordinary consumption is a separate question, and the research is still early. I'd be cautious about overclaiming here; a lot of what's circulating online about raw cannabinoids overstates what preliminary cell-culture and rodent data can actually tell us.

CBDA, THCA and the current research picture

There's a small but growing body of peer-reviewed work on the acidic forms, separate from the decades of research on CBD and THC. Researchers at institutions including the Hebrew University of Jerusalem, where Raphael Mechoulam's group has historically been active, have published on the pharmacological profiles of acidic cannabinoids. A 2020 paper in the British Journal of Pharmacology by Pertwee and colleagues mapped binding affinities across the cannabinoid acid series with considerably more rigour than most earlier work.

The honest summary of where this science sits: the acidic forms have distinct receptor-level pharmacology from their neutral counterparts, and those distinctions are real and replicable in in vitro settings. What we don't yet have is a thorough clinical picture translating in vitro findings into human pharmacokinetics. The first-pass metabolism story for ingested THCA and CBDA, for instance, isn't fully characterised.

Other acidic forms worth knowing

Beyond THCA, CBDA, and CBGA, the acidic series includes CBCA (cannabichromenic acid, precursor to CBC), CBDVA (precursor to CBDV), and THCVA (precursor to THCV). Each follows the same decarboxylation logic; each neutral form has a distinct receptor-interaction profile.

There's also the question of degradation products. When neutral cannabinoids oxidise over time, they can convert further; THC, for instance, degrades to CBN (cannabinol) under oxidative conditions. So the full picture of what's in any given cannabis preparation involves not just the acid-to-neutral decarboxylation step, but also subsequent degradation chemistry. Proper storage, inert atmosphere, and temperature control all affect what the molecule looks like by the time it reaches analysis or consumption.

Why this matters for Australian regulated cannabis products

In Australia, medicinal cannabis products approved through the TGA's Australian Register of Therapeutic Goods (ARTG) or accessed via the Special Access Scheme are required to meet manufacturing standards under Good Manufacturing Practice. Certificate of Analysis documentation for these products will typically specify cannabinoid content in terms of both acidic and neutral forms, or as "total THC" and "total CBD", calculated values that assume complete decarboxylation using the standard conversion factors (total THC = THC + 0.877 × THCA, for instance).

That conversion factor (0.877) comes directly from the molecular weight ratio of THCA to THC, the carboxyl group accounts for roughly 12.3% of THCA's molecular mass, so the neutral THC you'd get from fully decarboxylating a given mass of THCA is proportionally less. It's straightforward chemistry, but it matters enormously for accurate dosing labelling. Products regulated as Schedule 8 controlled drugs (THC-containing) or Schedule 4 prescription-only (low-THC CBD) in Australia must have this labelling right.

I spent an afternoon last year going through several publicly available Certificates of Analysis for ARTG-listed cannabis products; most do now report both acid and neutral figures, which is an improvement over what I was seeing three or four years ago. Still, not all are presented in a way that makes the distinction obvious to a prescriber who hasn't thought hard about the chemistry.

The raw cannabis question

There's ongoing curiosity about consuming raw cannabis, juicing fresh leaves, for instance, specifically to access the acidic forms without decarboxylating them. The interest is understandable from a phytochemistry standpoint. But this sits well outside any regulatory framework in Australia; cannabis as a fresh food product isn't an approved category, and the research supporting specific outcomes from acidic cannabinoid consumption in humans is not at a stage where anyone should be drawing firm conclusions. The molecular biology is interesting. The clinical translation is still mostly theoretical.

The plant does something remarkable with these molecules; the biosynthetic elegance of the CBGA branch point genuinely impresses me every time I revisit it. But impressive chemistry doesn't automatically translate into predictable effects in a living human, and that gap is where a lot of oversimplified content goes wrong.

Sources

• Cannabinoid Acids: Chemistry, Pharmacology and Their Role in Phytocannabinoid Research; NCBI / PubMed Central
• Medicinal Cannabis Guidance Documents, Therapeutic Goods Administration (TGA)
• An Update on the Endocannabinoid System and the Pharmacology of Cannabinoid Acids, NCBI / PubMed Central
• Cannabis and Cannabis-Related Substances: WHO Pre-Review Report; World Health Organization

, Elise Tran, Science writer, cannabinoids & the ECS

]]>